EP4135710A4 - Compositions that preferentially potentiate subtypes of gabaa receptors and methods of use thereof - Google Patents

Compositions that preferentially potentiate subtypes of gabaa receptors and methods of use thereof Download PDF

Info

Publication number
EP4135710A4
EP4135710A4 EP20872608.3A EP20872608A EP4135710A4 EP 4135710 A4 EP4135710 A4 EP 4135710A4 EP 20872608 A EP20872608 A EP 20872608A EP 4135710 A4 EP4135710 A4 EP 4135710A4
Authority
EP
European Patent Office
Prior art keywords
subtypes
compositions
methods
gabaa receptors
potentiate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20872608.3A
Other languages
German (de)
French (fr)
Other versions
EP4135710A1 (en
Inventor
Andrew D. LEVIN
Neil Buckley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eliem Therapeutics UK Ltd
Original Assignee
Eliem Therapeutics UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eliem Therapeutics UK Ltd filed Critical Eliem Therapeutics UK Ltd
Publication of EP4135710A1 publication Critical patent/EP4135710A1/en
Publication of EP4135710A4 publication Critical patent/EP4135710A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EP20872608.3A 2019-09-30 2020-09-23 Compositions that preferentially potentiate subtypes of gabaa receptors and methods of use thereof Pending EP4135710A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962907763P 2019-09-30 2019-09-30
PCT/US2020/052167 WO2021067089A1 (en) 2019-09-30 2020-09-23 Compositions that preferentially potentiate subtypes of gabaa receptors and methods of use thereof

Publications (2)

Publication Number Publication Date
EP4135710A1 EP4135710A1 (en) 2023-02-22
EP4135710A4 true EP4135710A4 (en) 2023-12-06

Family

ID=75338529

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20872608.3A Pending EP4135710A4 (en) 2019-09-30 2020-09-23 Compositions that preferentially potentiate subtypes of gabaa receptors and methods of use thereof

Country Status (9)

Country Link
EP (1) EP4135710A4 (en)
JP (1) JP2022552788A (en)
KR (1) KR20220103707A (en)
CN (1) CN115087450A (en)
BR (1) BR112022006085A2 (en)
CA (1) CA3159087A1 (en)
IL (1) IL291835A (en)
MX (1) MX2022003823A (en)
WO (1) WO2021067089A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4161530A4 (en) * 2020-06-08 2024-06-26 Eliem Therapeutics (UK) Ltd Methods of treating female health conditions related to sex hormones
WO2024020953A1 (en) * 2022-07-28 2024-02-01 湖南科益新生物医药有限公司 Steroid compound for treating central nervous system disease, method for preparing same, and use and pharmaceutical composition thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016061527A1 (en) * 2014-10-16 2016-04-21 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
PT3498725T (en) * 2013-04-17 2021-09-09 Sage Therapeutics Inc 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for use in therapy
CN109890392A (en) * 2016-10-14 2019-06-14 马瑞纳斯制药公司 Method of the application neurosteroid to realize electroencephalogram (EEG) outburst inhibition
WO2020210116A1 (en) * 2019-04-08 2020-10-15 Athenen Therapeutics, Inc. Steroids with altered pharmacokinetic properties and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016061527A1 (en) * 2014-10-16 2016-04-21 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders

Also Published As

Publication number Publication date
CA3159087A1 (en) 2021-04-08
IL291835A (en) 2022-06-01
EP4135710A1 (en) 2023-02-22
WO2021067089A1 (en) 2021-04-08
BR112022006085A2 (en) 2023-03-14
CN115087450A (en) 2022-09-20
JP2022552788A (en) 2022-12-20
KR20220103707A (en) 2022-07-22
MX2022003823A (en) 2022-08-17

Similar Documents

Publication Publication Date Title
EP3704239A4 (en) Casz compositions and methods of use
IL261283A (en) Compositions and methods using same for deposition of silicon-containing film
EP3595653A4 (en) Compositions of plinabulin and use thereof
EP3576782A4 (en) Construct-peptide compositions and methods of use thereof
EP3962527A4 (en) Chimeric receptors and methods of use thereof
EP3704254A4 (en) Cas12c compositions and methods of use
EP3423453A4 (en) The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors
EP3435956A4 (en) Photo-stabilized compositions and methods of use
EP3534710A4 (en) Coating compositions and methods of use thereof
EP3407976A4 (en) Compositions and uses of alpha-adrenergic agents
EP3864142A4 (en) Chimeric antigen receptors (cars) compositions and methods of use thereof
EP3802553A4 (en) Silicon-containing compositions and their methods of use
EP3600372A4 (en) Synthekine compositions and methods of use
EP3265127A4 (en) Use of glucocorticoid receptor antagonist and somatostatin analogues to treat acth-secreting tumors
EP3829307A4 (en) Bismuth-thiol compositions and methods of use
EP4135710A4 (en) Compositions that preferentially potentiate subtypes of gabaa receptors and methods of use thereof
SG11202106585UA (en) Polishing compositions and methods of using same
EP3688011A4 (en) Peptide compositions and methods of use thereof
IL276135A (en) Compositions and methods of use
IL264682B (en) 5-ht2c receptor agonists and compositions and methods of use
EP3606493A4 (en) Dental cement compositions and methods of use
EP3472260A4 (en) Compositions and methods for preparation and utilization of acid-generating materials
EP3891247A4 (en) Geopolymer cement compositions and methods of use
EP3700519A4 (en) Cannabinoid compositions and methods of use therof
EP3768315A4 (en) Fc variant compositions and methods of use thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220331

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230503

A4 Supplementary search report drawn up and despatched

Effective date: 20231107

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/30 20060101ALI20231031BHEP

Ipc: A61P 25/28 20060101ALI20231031BHEP

Ipc: A61P 25/24 20060101ALI20231031BHEP

Ipc: A61P 25/22 20060101ALI20231031BHEP

Ipc: A61P 25/18 20060101ALI20231031BHEP

Ipc: A61P 25/14 20060101ALI20231031BHEP

Ipc: A61P 25/08 20060101ALI20231031BHEP

Ipc: A61P 25/04 20060101ALI20231031BHEP

Ipc: A61P 25/00 20060101ALI20231031BHEP

Ipc: C07J 43/00 20060101ALI20231031BHEP

Ipc: A61K 31/58 20060101AFI20231031BHEP